Bibliographic Details
| Title: |
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study |
| Authors: |
Anıl Tombak, Mehmet Ali Uçar, Aydan Akdeniz, Eyüp Naci Tiftik, Deniz Gören Şahin, Olga Meltem Akay, Murat Yıldırım, Oral Nevruz, Cem Kis, Emel Gürkan, Şerife Medeni Solmaz, Mehmet Ali Özcan, Rahşan Yıldırım, İlhami Berber, Mehmet Ali Erkurt, Tülin Fıratlı Tuğlular, Pınar Tarkun, İrfan Yavaşoğlu, Mehmet Hilmi Doğu, İsmail Sarı, Mustafa Merter, Muhit Özcan, Esra Yıldızhan, Leylagül Kaynar, Özgür Mehtap, Ayşe Uysal, Fahri Şahin, Ozan Salim, Mehmet Ali Sungur |
| Source: |
Turkish Journal of Hematology, Vol 33, Iss 4, Pp 273-280 (2016) |
| Publisher Information: |
Galenos Publishing House, 2016. |
| Publication Year: |
2016 |
| Collection: |
LCC:Diseases of the blood and blood-forming organs |
| Subject Terms: |
azacitidine, acute myeloid leukemia, elderly, bone marrow blasts, prognostic factors, overall survival, Diseases of the blood and blood-forming organs, RC633-647.5 |
| More Details: |
Objective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of ≥60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment.nMedian overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
1308-5263 |
| Relation: |
https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-55632; https://doaj.org/toc/1308-5263 |
| DOI: |
10.4274/tjh.2015.0203 |
| Access URL: |
https://doaj.org/article/991999bdfbb345eea13143fc24d2544e |
| Accession Number: |
edsdoj.991999bdfbb345eea13143fc24d2544e |
| Database: |
Directory of Open Access Journals |
